Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018
March 28, 2019 at 05:32 pm IST
Share
Cardax, Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was USD 1.510 million compared to USD 610,323 a year ago. Operating loss was USD 4.022 million compared to USD 2.002 million a year ago. Net loss was USD 4.024 million compared to USD 1.985 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.
Cardax, Inc. is a consumer health company focused on marketing ZanthoSyn, an astaxanthin dietary supplement for inflammatory health. It seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. It intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.
CARDAX, INC. 
